Abstract
Sorsby fundus dystrophy (SFD) is a rare autosomal dominant macular degeneration characterized by abnormal thickening of Bruch’s membrane (BM) leading to macular atrophy and choroidal neovascularization (CNV). SFD is caused by mutations in the gene encoding the tissue inhibitor of metalloproteinase-3 (TIMP3), a multifunctional protein component of BM. Disturbed homeostasis in extracellular matrix (ECM) remodeling is likely involved in SFD pathology. Here, we summarize the current findings on the mechanism(s) by which mutant TIMP3 causes the phenotypical expression of SFD. In addition, the association between SFD and complex age-related macular degeneration (AMD) is discussed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Arris CE, Bevitt DJ, Mohamed J et al (2003) Expression of mutant and wild-type TIMP3 in primary gingival fibroblasts from Sorsby’s fundus dystrophy patients. Biochim Biophys Acta 1638:20–28
Barbazetto IA, Hayashi M, Klais CM et al (2005) A novel TIMP3 mutation associated with Sorsby fundus dystrophy. Arch Ophthalmol 123:542–543
Brew K, Nagase H (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803:55–71
Capon MRC, Marshall J, Krafft JI et al (1989) Sorsby’s fundus dystrophy: a light and electron microscopic study. Ophthalmology 96:1769–1777
Chen W, Stambolian D, Edwards AO et al (2010) Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci USA 107:7401–7406
Chong NH, Alexander RA, Gin T et al (2000) TIMP-3, collagen, and elastin immunohistochemistry and histopathology of Sorsby’s fundus dystrophy. Invest Ophthalmol Vis Sci 41:898–902
Clarke M, Mitchell KW, Goodship J et al (2001) Clinical features of a novel TIMP-3 mutation causing Sorsby’s fundus dystrophy: implications for disease mechanism. Br J Ophthalmol 85:1429–1431
Ebrahem Q, Qi J, Sugimoto M et al. (2011) Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3. Invest Ophthalmol Vis Sci 52:6117-6123
Fariss RN, Apte SS, Luthert PJ et al (1998) Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby’s fundus dystrophy or retinitis pigmentosa. Br J Ophthalmol 82:1329–1334
Fedak PW, Smookler DS, Kassiri Z et al (2004) TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110:2401–2409
Felbor U, Stöhr H, Amann T et al (1995) A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby’s fundus dystrophy with unusual clinical features. Hum Mol Genet 4:2415–2416
Felbor U, Benkwitz C, Litt M et al (1997) A founder mutation in TIMP3, Ser181Cys, presents with variable expressivity of Sorsby fundus dystrophy. Arch Ophthalmol 115:1569–1571
Fogarasi M, Janssen A, Weber BH et al (2008) Molecular dissection of TIMP3 mutation S156C associated with Sorsby fundus dystrophy. Matrix Biol 27:381–292
Fu L, Garland D, Yang Z et al (2007) The R345W mutation in EFEMP1 is pathogenic and causes AMD-like deposits in mice. Hum Mol Genet 16:2411–2422
Jacobson SG, Cideciyan AV, Regunath G et al (1995) Night blindness in Sorsby’s fundus dystrophy reversed by vitamin A. Nat Genet 11:27–32
Jacobson SG, Cideciyan AV, Bennett J et al (2002) Novel mutation in the TIMP3 gene causes Sorsby fundus dystrophy. Arch Ophthalmol 120:376–379
Janssen A, Hoellenriegel J, Fogarasi M et al (2008) Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloprotease-3. Invest Ophthalmol Vis Sci 49:2812–2822
Kamei M, Hollyfield JG (1999). Invest Ophthalmol Vis Sci 40:2367–2375
Klenotic PA, Munier FL, Marmorstein LY et al (2004) Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem 279:30469–30473
Langton KP, McKie N, Curtis A et al (2000) A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby’s fundus dystrophy. J Biol Chem 275:27027–27031
Langton KP, McKie N, Smith BM et al (2005) Sorsby’s fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells. Hum Mol Genet 14:3579–3586
Leco KJ, Waterhouse P, Sanchez OH et al (2001) Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 108:817–829
Lin RJ, Blumenkranz MS, Binkley J et al (2006) A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy. Am J Ophthalmol 142:839–848
Mahmoodi M, Sahebjam S, Smookler D et al (2005) Links Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. Am J Pathol 166:1733–1740
Mohammed FF, Smookler DS, Taylor SE et al (2004) Abnormal TNF activity in Timp3 −/− mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet 36:969-977
Polkinghorne PJ, Capon MRC, Berninger T et al (1989) Sorsby’s fundus dystrophy: a clinical study. Ophthalmology 96: 1763–1768
Qi JH, Dai G, Luthert P et al (2009) S156C mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis. J Biol Chem 284:19927–19936
Qi JH, Ebrahem Q, Moore N et al (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9:407–415
Qi JH, Ebrahem Q, Yeow K et al (2002) Expression of Sorsby’s fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis. J Biol Chem 277:13394–13400
Saihan Z, Li Z, Rice J et al (2009) Clinical and biochemical effects of the E139K missense mutation in the TIMP3 gene, associated with Sorsby fundus dystrophy. Mol Vis 15:1218–1230
Sivaprasad S. Webster AR, Egan CA et al (2008) Clinical Course and Treatment Outcomes of Sorsby Fundus Dystrophy. Am J Ophthalmol 146:228–234
Soboleva G, Geis B, Schrewe H et al (2003) Sorsby fundus dystrophy mutation Timp3(S156C) affects the morphological and biochemical phenotype but not metalloproteinase homeostasis. J Cell Physiol 197:149–156
Sorsby A, Mason MEJ, Gardner N (1949) A fundus dystrophy with unusual features (late onset and dominant inheritance of a central retinal lesion showing oedema, haemorrhage and exudates developing into generalised choroidal atrophy with massive pigment proliferation). Br J Ophthalmol 33: 67–97
Tabata Y, Isashiki Y, Kamimura K et al (1998) A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorsby’s fundus dystrophy with unusual clinical features. Hum Genet 103:179–182
Troeberg L, Fushimi K, Khokha R et al (2008) Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J 22:3515–3524
Weber B, Vogt G, Pruett RC et al (1994) Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby’s fundus dystrophy. Nat Genet 8:352–356
Weber BH, Lin B, White K et al (2002) A mouse model for Sorsby fundus dystrophy. Invest Ophthalmol Vis Sci 43:2732–2740
Yeow KM, Kishnani NS, Hutton M et al (2002) Sorsby’s fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix. Matrix Biol 21:75–88
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this paper
Cite this paper
Stöhr, H., Anand-Apte, B. (2012). A Review and Update on the Molecular Basis of Pathogenesis of Sorsby Fundus Dystrophy. In: LaVail, M., Ash, J., Anderson, R., Hollyfield, J., Grimm, C. (eds) Retinal Degenerative Diseases. Advances in Experimental Medicine and Biology, vol 723. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0631-0_34
Download citation
DOI: https://doi.org/10.1007/978-1-4614-0631-0_34
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-0630-3
Online ISBN: 978-1-4614-0631-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)